| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Sep 27, 2021Lecanemab Is An Anti-Amyloid Beta (Aβ) Protofibril Antibody
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") today announced...
- Sep 13, 2021Subgroup analyses from registrational Phase 3 KEYNOTE-775/Study 309 and CLEAR/KEYNOTE-581 trials provide additional data on KEYTRUDA (pembrolizumab) plus LENVIMA (lenvatinib)
Eisai Inc. announced today the presentation of 13 abstracts across multiple types of cancer from its oncology portfolio during the upcoming European Society for Medical Oncology (ESMO) Congress...
- Aug 30, 2021
Eisai today announced that H3 Biomedicine (H3), its cancer genomics-based drug discovery subsidiary company located in Cambridge, Mass., has appointed a new executive leadership team. Ping Zhu,...
- Aug 11, 2021KEYTRUDA Plus LENVIMA Is Now Approved for Two Types of Cancer, Including Advanced RCC
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., Aug. 11, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug...
- Aug 5, 2021
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the appointment of Janna Hutz, Ph.D., as President of the Eisai Center for Genetics Guided Dementia Discovery...
- Jul 29, 2021Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following 18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof of Concept Study at 2021 Alzheimer's Association International Conference (AAIC)
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") today announced...
- Jul 29, 2021• ICARE AD-US is an observational real-world phase 4 study designed to evaluate the safety and effectiveness of ADUHELM in clinical practice
CAMBRIDGE, Mass., July 29, 2021 – Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo) today announced that Biogen will lead a late-breaking presentation on the design of the first real-world...
- Jul 26, 2021Item-level analysis from EMERGE trial shows consistency in slowing decline across cognitive, functional and behavioral measures in early Alzheimer’s disease
CAMBRIDGE, Mass., July 26, 2021 -- Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen, as part of its Alzheimer’s disease (AD) research portfolio, will...
- Jul 22, 2021- Lecanemab Late-Breaker: Oral Presentation of Preliminary Assessment of Lecanemab's Clinical Effects from Open Label Extension Phase 2 Proof of Concept Study in Subjects with Early Alzheimer's Disease
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of findings from the company's robust Alzheimer's disease (AD) pipeline, including lecanemab...
- Jul 22, 2021Immunotherapy and Tyrosine Kinase Inhibitor Combination Approved for the Treatment of Patients With Advanced Endometrial Carcinoma That is Not Microsatellite Instability-High or Mismatch Repair Deficient, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are Not Candidates for Curative Surgery or Radiation
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., July 22, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced that the U.S. Food and Drug...
- Jul 8, 2021ADUHELM should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia
CAMBRIDGE, Mass. and TOKYO, JULY 8, 2021 (GLOBE NEWSWIRE) – Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced the U.S. Food and Drug Administration (FDA) has approved an...
- Jun 28, 2021
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Andree Amelsberg, M.D., MBA, as Vice President, U.S. Medical Affairs, Oncology...
- Jun 23, 2021
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") today announced...
- Jun 23, 2021
CAMBRIDGE, Mass. and WOODCLIFF LAKE, N.J., June 23, 2021 – Biogen (Nasdaq: BIIB) and Eisai Inc., U.S. subsidiary of Eisai Co., Ltd. today issued the following statement: On June 7, 2021,...
- Jun 18, 2021
TOKYO AND NEW YORK, June 18, 2021 -- Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the companies have entered into an exclusive global strategic collaboration...
- Jun 9, 2021Presentations featuring data evaluating DAYVIGO in insomnia highlighting the impact for appropriate patients
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today new presentations featuring the latest data about the company's insomnia medication DAYVIGO (lemborexant) will be...
- Jun 7, 2021Programs now available to support patients and families with their treatment journey
CAMBRIDGE, Mass. and WOODCLIFF LAKE, N.J., June 07, 2021 (GLOBE NEWSWIRE) -- Following today’s U.S. Food and Drug Administration’s (FDA) accelerated approval of ADUHELMTM (aducanumab-avwa) as...
- Jun 7, 2021The accumulation of amyloid beta plaques in the brain is a defining pathology of Alzheimer’s disease
CAMBRIDGE, Mass. and TOKYO, June 7, 2021 (GLOBE NEWSWIRE) – Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has granted...
- Jun 7, 2021Results From New Analysis Evaluating Health-Related Quality of Life (HRQoL) Based on Patient-Reported Outcomes Using Three HRQoL Scales
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., June 7, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced new investigational data from the...
- May 24, 2021
Hackensack Meridian Health, New Jersey's largest, most comprehensive and integrated health network, and Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., have entered into a...
- May 18, 2021- Data include landmark median progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) in patients, including those with triple-negative breast cancer (TNBC)
Eisai today announced results from a real-world study assessing treatment patterns and clinical outcomes with HALAVEN® (eribulin mesylate) injection as a third-line therapy or greater in patients...
- May 17, 2021Eisai to present more than 25 abstracts including investigational data on oncology pipeline and products
Eisai Inc. announced today the presentation of more than 25 abstracts across various types of cancer from its oncology portfolio during the virtual scientific program of the 2021 American Society...
- May 6, 2021Applications Based on Progression-Free Survival, Overall Survival, and Objective Response Rate Data From Respective Pivotal Phase 3 Trials
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., May 6, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced that the U.S. Food and Drug...
- Apr 29, 2021
Eisai announced today that the European Journal of Cancer published the results from a post hoc analysis of the Phase 3 SELECT study evaluating the impact of lung metastases on overall survival...
- Apr 19, 2021Lecanemab Phase 3 Clarity AD Clinical Trial Completed Enrollment
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") today announced...
